Amplia Therapeutics Ltd. (AU:ATX)
ASX:ATX
Want to see AU:ATX full AI Analyst Report?
ATX Stock Chart & Stats
AU$0.14
<AU$0.01(2.33%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(2.33%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.43
Previous CloseN/A
Volume274.48K
Average Volume (3M)525.22K
Market Cap
AU$56.46M
Enterprise ValueAU$41.75M
Total Cash (Recent Filing)AU$27.85M
Total Debt (Recent Filing)AU$341.11K
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding513,312,000
10 Day Avg. Volume444,673
30 Day Avg. Volume525,217
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-12.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused FAK-targeted Therapeutic PlatformA concentrated R&D focus on the FAK pathway creates durable scientific differentiation in oncology and fibrosis. Specialization enables efficient resource allocation, deeper domain expertise, and clearer go-to-market positioning, improving odds of attractive partnerships and licensing over the next 2–6 months.
Equity-backed Balance Sheet With Low LeverageA sizable equity cushion and historically low leverage give the company runway to fund ongoing R&D and clinical activities without immediate default risk. This balance-sheet strength reduces short-term insolvency risk and improves negotiating leverage with partners or licensors over coming quarters.
Partnership/licensing-centric Revenue ModelA business model built on partnerships and licensing is durable for early-stage biotech: it provides milestone-driven, non-dilutive financing, access to commercialization channels, and de-risks late-stage costs. This model supports program advancement even with limited internal commercial infrastructure.
Bears Say
Revenue Collapse To Zero In Latest YearA drop to zero revenue removes operating diversification and intensifies dependence on financing and partnerships. Over 2–6 months this elevates execution risk, constrains reinvestment in programs, and increases the probability of fundraising needs that may dilute shareholders or slow program timelines.
Worsening Cash Burn And Negative Operating Cash FlowConsistent negative operating and free cash flow with increasing burn undermines financial flexibility. Without near-term revenue or milestone receipts, the company will likely need additional funding within months, risking dilution, delayed trials, or slowed development if capital terms are unfavorable.
Persistent Net Losses And Negative ROEOngoing net losses and negative returns on equity indicate the capital base is not yet generating shareholder value. Over a multi-month horizon this can weaken bargaining power with partners, constrain strategic options, and force trade-offs between R&D progress and cash preservation.
Amplia Therapeutics News
ATX FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest share price was AU$0.06 and its highest was AU$0.42 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Amplia Therapeutics Ltd.’s market cap is AU$56.46M.
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is Nov 25, 2026 which is in 165 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on May 29, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 513,312,000 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amplia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
-18.71%
Trailing 12-Months
Asset Growth
98.58%
Trailing 12-Months
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics Limited is an Australian pharmaceutical company dedicated to pioneering focal adhesion kinase (FAK) inhibitors, with a focus on both oncology and chronic fibrotic diseases. A key asset in its development pipeline is AMP945, a FAK inhibitor that has successfully completed Phase I clinical trials. This compound is being advanced for a range of conditions, including pancreatic cancer, idiopathic pulmonary fibrosis, and other malignant and fibrotic disorders. Additionally, AMP886 is under development for similar cancer and fibrotic indications. The company maintains a collaborative research agreement with Sydney's Garvan Institute of Medical Research. Established in 2000, the firm was initially known as Innate Immunotherapeutics Limited before adopting the name Amplia Therapeutics Limited in September 2018, and its headquarters are located in Melbourne, Australia.
Technical Analysis
Tryptamine Therapeutics
―
Neuren Pharmaceuticals Limited
―
Paradigm Biopharmaceuticals
―
Alterity Therapeutics
―
Zelira Therapeutics
―
Options Prices
Currently, No data available
---